The Myeloma Beacon » Mozobil (plerixafor, AMD-3100)

Mozobil (plerixafor, AMD-3100)

By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled

Brand Name:	Mozobil
Generic Name:	plerixafor
Code Name:	AMD-3100
Company:	Genzyme
FDA Clinical Phase:	Approved for use with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into the peripheral blood for collection and subsequent autologous transplantation in multiple myeloma patients

Description:
Mozobil is a member of a new class of medications called "chemokine inhibitors". The drug triggers the movement of stem cells out of the bone marrow into the blood stream. Larger stem cell doses for transplantation are correlated to faster recovery times after high dose chemotherapy followed with stem cell transplantation.

Clinical Trials:
Currently, there are several open clinical studies ^[1] involving Mozobil.

Source: ClinicalTrials.gov, Multiple Myeloma AND Mozobil, http://www.clinicaltrial.gov/ct2/results?term=multiple+myeloma+AND+Mozobil ^[2] (as of September 4, 2008)

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2008/10/15/mozobil/

URLs in this post:

[1] clinical studies: http://www.clinicaltrial.gov/ct2/results?term=&recr=Open&type=&cond=multiple+myeloma&intr=Mozobil&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=

[2] http://www.clinicaltrial.gov/ct2/results?term=multiple+myeloma+AND+Mozobil: http://www.clinicaltrial.gov/ct2/results?term=multiple+myeloma+AND+Mozobil

Click here to print.